Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Amodiaquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 5/20 | 1.00 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.98 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.98 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HNMT | P50135 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amodiaquine SCHEMBL12094969 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29430175 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29788983 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL1491204 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL30903900 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29425350 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL44152 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL29441086 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| Amodiaquine SCHEMBL284774 | 0.97 | CYP2D6 (0.96) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 | |
| SCHEMBL20536537 | 0.93 | CYP2D6 (0.88) | CYP2D6CYP1A2CYP2C8CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105574-A1 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-29 | — | — | US | claimed |
| US-20080038770-A1 | Cancer Stem Cells And Uses Thereof | HOSPITAL FOR SICK CHILDREN (CA) | 2008-02-14 | — | — | US | claimed |
| WO-2007079293-A2 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2007-07-12 | — | — | WO | claimed |
| US-20070123448-A1 | Novel chemical entities affecting neuroblastoma tumor-initiating cells | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-05-31 | — | — | US | claimed |
| US-4806537-A | Use of amodiaquin and related compounds in treatment of nervous system degeneration | CITY OF HOPE (US) | 1989-02-21 | — | — | US | claimed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4593631-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | Mars, Incorporated (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073025-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4344552-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2021183463-A1 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20180289682-A1 | COMPOUNDS AND METHODS FOR PROMOTING STRESS RESISTANCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-10-11 | — | — | US | disclosed |
| US-20080178459-A1 | METHOD OF PRODUCING A RADIALLY EXPANDABLE PROSTHESIS | COOK INCORPORATED (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080038770-A1 | Cancer Stem Cells And Uses Thereof | HOSPITAL FOR SICK CHILDREN (CA) | 2008-02-14 | — | — | US | disclosed |
| US-20070207184-A1 | Implantable medical device coated with a bioactive agent | MED INSTITUTE, INC (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007089592-A2 | IMPLANTABLE MEDICAL DEVICE COATED WITH BIOACTIVE AGENT | MED INSTITUTE, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007079293-A2 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2007-07-12 | — | — | WO | disclosed |
| US-20070123448-A1 | Novel chemical entities affecting neuroblastoma tumor-initiating cells | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-05-31 | — | — | US | disclosed |
| US-4831033-A | BLOCKS POTASSIUM CHANNELS, INHIBITS CHOLINESTERASE | CITY OF HOPE (US) | 1989-05-16 | — | — | US | disclosed |
| US-4806537-A | Use of amodiaquin and related compounds in treatment of nervous system degeneration | CITY OF HOPE (US) | 1989-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289682-A1 | COMPOUNDS AND METHODS FOR PROMOTING STRESS RESISTANCE | HSPA9, ATF4, GPX4 | KCNH2 4377/4885GAA 1174/4885CHRM2 4616/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | KCNH2 4706/4885GAA 608/4885CHRM2 2576/4885 |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | HSPA9, ATF4, GPX4 | KCNH2 4377/4885GAA 1174/4885CHRM2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.